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Mitomycin C: small, fast and deadly (but very selective) 
Mitomycin C, an important antitumor drug and antibiotic, has an extraordinary ability 
to crosslink DNA with high efficiency and absolute specificity for the sequence CpG. 
Recent results have shown how mitomycin C crosslinks DNA, and why the sequence 
specificity is so complete. This new understanding may allow the design of agents that 
mimic mitomycin C’s economy of structure and can crosslink other sequences. 
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Mitomycin C (MC; compound 1, Fig. 1) is an antitumor 
antibiotic discovered in the 1950s by Japanese microbio- 
logists in fermentation cultures of the microorganism 
Stveptomyces caespitosus [l]. A number of close structural 
variants of MC have since been isolated, collectively called 
the mitomycins. MC has a variety of specif?c biological 
effects in mammalian cells, including selective inhibition of 
DNA synthesis, mutagenesis, and stimulation of genetic 
recombination, chromosome breakage and sister chromatid 
exchange, and induction of the DNA repair (SOS) response 
in bacteria [l]. It has therefore been widely used as a tool to 
study such phenomena. MC is also an important antitumor 
drug used widely in the clinic. 
which has not been fully characterized structurally [2]. 
DNA crosslinking agents, typically bifimctional alkylators 
like MC, have been synthesized, however, and have been 
widely used in cancer chemotherapy. A complete under- 
standing of MC’s mechanism of action, the identity of the 
DNA adducts it forms and the structure of the 
DNA-MC complex would help us understand how MC 
induces cell-cycle arrest and apoptosis, and would be 
invaluable in the design of drugs that aspire to mimic 
MC’s efficiency of action. New insight into these ques- 
tions has come in recent years from high-resolution 
NMR studies and molecular modeling. 
Reductive activation cascade of MC 
The molecular mechanism underlying the biological and MC itself (structure 1, Fig. 1) does not react with DNA. 
pharmacological properties of MC is unprecedented. In Upon enzymatic or chemical reduction of the quinone, 
1963 it was shown that MC crosslinks the complemen- however, a cascade of spontaneous transformations ensues, 
tary strands of the DNA double helix; this is so lethal that culminating in the opening of the aziridine ring to 
a single crosslink per genome is sufficient to cause death produce the unstable vinylogous quinone methide 2, 
of a bacterial cell [l]. No other natural antibiotic works which has high alkylating reactivity at the Cl position 
this way, with the possible exception of carzinophillin, (Fig. 1; [1,3-71). When compound 2 reacts with a DNA 
Mit&nycin C (MC) 
OH OH 
1 
Fig. 1. The reductive activation cascade of mitomycin C (MC) [I ,3-71. Reduction of the quinone of MC initiates a series of sponta- 
neous transformations culminating in the opening of the aziridine ring. The activated MC attacks DNA twice, resulting in covalent 
cross-linking of the strands of the DNA duplex. 
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nucleophile at Cl (to form adduct 3) a second alkylating 
center develops at Cl0 by reverse Michael elimination of 
the carbamate (adduct 4); this adduct is attacked by 
another DNA nucleophile to give the reoxidized DNA 
crosslink (adduct 5). Reduction thus converts MC into a 
highly reactive bifunctional alkylating agent. Several flavo- 
reductases are known to catalyze this transformation in 
bacterial and mammalian cells [8]. 
It is worth noting, in passing, that this activation scheme 
is remarkably similar to the reductive mechanism that 
activates another group of antibiotics, the enediynes 
(which have an entirely different type of structure and 
damage DNA by cleaving rather than crosslinking it). 
The DNA-cleaving activity of the enediyne dynemicin 
A, for example, is triggered by reduction of a quinone, 
resulting in opening of an originally inactive epoxide 
ring assisted by quinone methide formation [9]; this 
mechanism is strikingly similar to the assisted ring- 
opening of the originally inactive aziridine of MC, 
leading to quinone methide 2. 
The fact that MC is activated by reduction is important 
in the selectivity of its antitumor activity. Many solid 
Fig. 2. Adducts of MC and DNA formed 
by reductive activation. Activation of 
only one of the alkylating functions 
gives monoadduct 6, whereas activation 
of both alkylating functions can give 
products 7-9. MC is highlighted in pink. 
tumors are short of oxygen compared to normal tissues. 
As activation of MC is inhibited by an oxidizing envir- 
onment, MC has selective toxicity for these hypoxic solid 
tumors, and potently suppresses their growth [8]. This 
feature of MC’s design has frequently been imitated by 
pharmaceutical chemists; many new antitumor agents 
have been designed that are triggered by bioreduction, 
and several of them are under clinical development (see, 
for example, [lo]). 
Structures of MC-DNA adducts 
The chemical identity of the DNA crosslinks induced by 
reduced MC has been determined by isolating 
crosslinked nucleosides from MC-treated DNA. 
Monofunctionally alkylated nucleosides (monoadducts), 
formed at the same time as the crosslinked adduct were 
also isolated. The structures of all the major MC-DNA 
adducts formed in cell-free systems are shown in Figure 
2. Under reductive conditions, MC alkylates only the 
2-amino groups of guanine nucleosides, in the minor 
groove of DNA.The first alkylation step by the quinone 
methide 2 leads to monoadduct 6 [ll]; in some condi- 
tions, this is the only alkylation that occurs. Under con- 
ditions in which the second alkylating center develops, 
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however, bisadduct 7, which forms a crosslink between 
the DNA strands, is a major product [7]; less frequently, 
the second alkylation step yields bisadduct 9, a crosslink 
within one strand [12]. The lo”-decarbamoylated 
monoadduct 8 is also a major product of bifunctional 
activation, and results from nucleophilic attack by water 
at the ClO” position [13]. The same adducts have been 
detected and identified in viva [7,14]. 
Structure of MC-DNA complexes 
Early molecular modeling studies indicated that, like 
most natural antibiotics targeted at DNA, the MC 
molecule resides in the minor groove in the mono- 
adducts [l 1,15-171 and in the crosslinked adducts [7], 
and does not greatly perturb the structure of duplex 
DNA. A study in which the structure of a crosslinked 
hexanucleotide duplex was examined with two-dimen- 
sional NMR and restrained molecular mechanics com- 
putation was largely consistent with these models [18]. 
The structure of the monoadducts in DNA has become 
available only recently. A high-resolution structure of the 
MC monoadduct 6 formed with a nine-base-pair oligo- 
nucleotide duplex was obtained using two-dimensional 
NMR and restrained molecular dynamics calculations, 
inclulding NOE-intensity-based refinement ([19]; Fig. 3). 
In this structure, the mitomycin residue is lying inside 
the slightly widened minor groove, resulting in extensive 
non-Scovalent contacts between the drug and the DNA 
duplex. The indoloquinone ring system is found to be 
stacked on one side of the duplex along the backbone of 
the non-bonding strand. Although the details are differ- 
ent, this structure makes it clear that the most important 
elements of the earlier models were correct. It also clari- 
fies several aspects of MC’s mechanism of action and 
sequence selectivity 
Both alkylation steps are sequence-specific 
The first, monoalkylation step in the formation of the 
crosslinked adduct is selective for guanine nucleosides in 
the sequence 5’-CpG-3’ (hereafter CpG) [20,21], while 
the second step is absolutely specific for the same 
sequence [22-241. Th e selectivity of the first step is not 
dramatic; alkylation at CpG is on average five-fold [25] or 
ten-fold [21] enhanced over that at other NpG 
sequences.The second step, however, absolutely requires a 
G opposite the C. G residues flanking the NpG sequence 
on the opposite strand are never crosslinked, though 
intrastrand crosslinks can form on NpGpG sequences. 
The selectivity of the first step, though not absolute, is 
crucial for successful crosslinking and for the biological 
activity of MC, as we will see below. 
Surprisingly, the selectivity of the monoalkylation step 
requires not only a CpG sequence on the target strand, 
but also a G residue on the opposite strand.The selectiv- 
ity of MC for CpG can be abolished by replacing the 
guanine nucleoside in the opposite strand, which pairs 
with the C of the CpG, with inosine. Thus, the 2-NH, 
group of the opposite-strand guanine is essential for 
selective monoalkylation. It was proposed that this group 
Fig. 3. Structure of the MC-DNA monoadduct. (a) Minor-groove 
view of the central four base pairs of the monoalkylated 
complex between MC and the double-stranded oligonucleotide 
d(l-C-A-C-[MC]C-T-C-I-T)*d(A-C-G-A-C-G-T-C-C). I, inosine; 
residues are numbered sequentially from the left. The MC 
residue is shown in blue. The white solid arrow indicates the 
covalent linkage of Cl ” of MC to G5 as in adduct 6. The white 
dotted arrow points to the ClO” oxygen atom of MC and the 
exposed N* hydrogen atom of G15, which are located close 
enough together to form an H-bond. (b) Same as (a), using 
space-filling model. The one-sided stacking of the MC chro- 
mophore with the backbone of the non-bonded strand (left side) 
is apparent. (c) Model in (a) is rotated to make visible the 
H-bond between the Cl 0” oxygen atom of MC and the exposed 
N2 hydrogen atom of G15 (white dotted line). 
can form a specific H-bond with the ClO” oxygen atom 
of activated MC (see Fig. 2) and that this non-covalent 
bond increases the rate of formation of the covalent bond 
with the target guanine [21,25] (Fig. 4). Modeling studies 
[11,15-17,251 supported this suggestion, and the recent 
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high-resolution structure of the MC-oligonucleotide 
monoadduct [19] decisively shows that the MC residue is 
indeed aligned in the minor groove to form this specific 
H-bond (Fig. 3). One can assume, therefore, that before 
the first covalent bond between MC and DNA is formed 
the opposite-strand G has already been recognized by 
H-bonding, and that the monoadduct structure is a 
trapped form of this pre-covalent complex. 
It has been very difficult to examine the non-covalent 
binding of MC to DNA directly. Unreduced MC does 
not bind to DNA and the reductively activated form, 
compound 2, is too short-lived for direct study. 
Nevertheless, there is evidence for the non-covalent 
binding of compound 2 to DNA from two different 
investigations [22,26]. Our laboratory [26] used the stable 
oxidized form of compound 2, 2,74iaminomitosene, 
which is positively charged, and found that it intercalates 
non-specifically into DNA, with a binding constant in 
the range of lo4 M-l. Although this does not help us to 
examine the CpG-specific minor-groove binding that 
precedes the covalent reaction, this bulk, non-specific 
binding mode is presumably important to attract activated 
MC to DNA. The CpG-specific minor-groove binding is 
an alternative pre-covalent binding mode, in equilibrium 
with non-specific binding. It is interesting to note that 
the unnatural enantiomer of MC recognizes CpG in 
DNA by the same mechanism as MC, as indicated by the 
CpG-specificity of the alkylation, the similar orientation 
of the compound in the minor groove and the identical 
chirality of the drug-DNA bond [27]. 
As noted above, crosslinking by MC is absolutely specific 
for the duplex DNA sequence CpG*CpG (Fig. 5); 
crosslinks to neighboring guanines never form. What 
determines the remarkable specificity of the second alky- 
lation step? In the high-resolution NMR structure of the 
monoadduct-oligonucleotide complex (Fig. 3) it can be 
clearly seen that the monoadduct is oriented in the minor 
groove so that its ClO” carbamate is pointing towards the 
3’ 5’ 
Fig. 4. Schematic illustration of a CpG sequence-specific H-bond 
(dotted line) between the CIO” oxygen atom of the activated 
form of MC and DNA. The structure in pink symbolizes activated 
MC (3); its IO”-carbamate and 2”-NH,(+) functional groups 
are shown. The arrow points to the guanine nucleoside that is 
targeted for the covalent reaction. 
CG*CG crosslink 
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formed exclusively 
Fig. 5. Exclusive cross-linking of the CG*CG sequence by the 
MC-monoadduct. Arrows point to guanines in different positions 
relative to the monoadduct which are potential targets to form a 
crosslink. The solid arrow points to the only cross-link observed 
experimentally. Broken arrows l-3 would lead to GC*GC, 
GN,C*GN’,C and CN,G*CN’,G crosslinks, respectively. Such 
cross-links are formed frequently with other cross-linking agents 
but not with MC. 
5’ end of the strand to which it is linked (therefore, 
towards the opposite-strand G), and is close enough 
(within 3.3 A) to the N2-atom of the unbonded guanine 
to form an H-bond with it. Thus the monoadduct is 
poised to form the crosslink without significant structural 
reorganization of the DNA 1191. At other sequences the 
monoadduct ClO” position does not have a second N2 
atom within range, and is attacked by water to yield com- 
pound &The covalent monoadduct is trapped by the Cl” 
covalent bond to DNA in the proper orientation to form 
a crosslink; although the H-bond between the ClO” 
oxygen atom and the N2 hydrogen atom of the 
unbonded guanine is necessary to enhance formation of 
the monovalent adduct, once the covalent bond is 
formed, the H-bond is no longer essential to maintain 
this orientation [19]. 
Why be sequence-selective? 
Reduced MC has strong intrinsic base- and regio- 
specific reactivity for the N2 of guanine, even in a 
monomeric form [28].Thus, MC requires two G residues 
on opposite strands to form a crosslink.The only way to 
be sure that there will be two G residues close to each 
other on opposite strands is to select for a CpG sequence. 
The pre-covalent sequence selectivity described above is 
thus a mechanism to ensure that MC monoalkylates only 
those guanines that will allow crosslinking. As a result, 
relatively few of the available drug molecules will be 
wasted by alkylating DNA at sites such as ApG,TpG and 
GpG, where only monoadducts (which are less often 
lethal) can be formed. The ability of MC to selectively 
recognize and alkylate its crosslinkable target must have 
made it a more potent weapon against competing 
microorganisms. Although other natural products seem to 
be sequence-selective for no good teleological reason, the 
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sequence selectivity of MC appears to be the result of 
natural selection to optimize its biological function. 
Drug design: making a good. machine even better 
The site-specific, non-distorting, highly efficient 
crosslinking mechanism of the natural product MC 
stands in sharp contrast to the generally non-specific 
action of synthetic antitumor crosslinking agents, for 
example the N-mustard mechlorethamine, or the 
quinone-aziridines diaziquone (AZQ) and diaziridinyl 
benzoquinone (DZQ), which produce heterogenous 
mixtures of DNA crosslinks in low yield, accompanied 
by a large excess of non-specific monoadducts [29,30]. 
MC, in contrast, is an efficient DNA crosslinking 
machine. With the mechanism of this machine now 
well understood, it is not difficult to imagine new syn- 
thetic or semisynthetic structures that imitate MC, pre- 
selecting crosslinkable DNA sequences and using the 
same efficient crosslinking chemistry. It may be possible 
to design structures that crosslink the same sequence 
with improved efficiency, or that crosslink different 
sequences. Specificity for the sequence CpG, which is 
rare in mammalian genomes, does not seem ideal for a 
compound that is used as an antitumor agent. Only 5 % 
of all guanines in the mammalian genome are present 
in the CpG context, compared to 70 % (!) in the case of 
A4~cro~coccus luteus DNA, for example. As a result, 
mammalian DNA is crosslinked by MC relatively 
poorly [l]. Although the sequence specificity of MC 
was presumably advantageous for its original purpose, 
improving the chances of killing competing microor- 
ganisms, it must be a disadvantage for killing tumor 
cells. Retaining the potent crosslinking mechanism of 
MC but altering or even relaxing its sequence speci- 
ficity may allow the design of crosslinking agents that 
are more efficacious against tumors than MC itself. 
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